Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.
Industry sector: Medical
Sector classification: Biological products, except diagnostic
Deep Learning based analysis and prediction model for Amgen Inc. (AMGN) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.
Model is in the production pipeline since Sept. 30, 2015.
Market data for AMGN model training are being downloaded from the
Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are
accounted for in this model in the form of the historical data coincided with outbreaks and other
global events in the past used to train ML prediction model for AMGN.
Model is being retrained on a regular basis.
| Float | 660M |
| P/E | 13.13 |
| Shares Outstanding | 662M |
| % Held by Insiders | 0.19% |
| % Held by Institutions | 85.73% |
| EPS (last reported FY) | $12.58 |
| EPS (last reported Q) | $3.47 |
| EPS, estimated (last reported Q) | $3.23 |
| Total revenues | $23 B |
| Net income | $2 B |